64Cu-SAR-bisPSMA (Clarity Pharmaceuticals)

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug Name64Cu-SAR-bisPSMA (Clarity Pharmaceuticals)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Nuclides > Copper > 64CuRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionProstate-Specific Membrane Antigen inhibitors

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPuerto RicoAustralia

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesClarity Pharmaceuticals Ltd

China Registration ClassN/A

Develop Information

Active CompaniesClarity Pharmaceuticals Ltd

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A